All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Treatment sequencing for anemic myelofibrosis
with Jean-Jacques Kiladjian & Angela Fleischman
Monday, February 26, 2024 | 16:30 CET
This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
Bookmark this article
During the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the MPN Hub was pleased to speak to Helen Ajufo, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What implications might the PERSIST-2 landmark overall survival (OS) analysis data have on the use of pacritinib in myelofibrosis?
What implications might the PERSIST-2 landmark OS analysis data have on the use of pacritinib in MF?
In this interview, Ajufo shares insights on the latest analysis from the PERSIST-2 trial on spleen reduction as a predictor of OS in pacritinib-treated myelofibrosis. Ajufo discusses the OS data, stratified by patient platelet count and spleen volume reduction achieved, making comparisons with corresponding data from the control arm of best available therapy. This interview concludes with a look at the future application of pacritinib in myelofibrosis.
Pacritinib shows symptom and spleen response regardless of cytopenias in patients with MF
Here, we summarize a retrospective analysis presented by Bose at #ASCO23, they investigated the effects of pacritinib on spleen and symptom benefit across the...
New drug application (NDA) for accelerated FDA approval to be submitted for pacritinib in treating myelofibrosis with severe thrombocytopenia
The U.S Food and Drug Administration (FDA) has agreed to a new drug application (NDA) submission which may...
Subscribe to get the best content related to MPN delivered to your inbox